Who are FOLFIRI regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "FOLFIRI" cures.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfiri-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FOLFIRI regimen — Competitive Intelligence Brief

FOLFIRI regimen (FOLFIRI regimen) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen (combination of antimetabolite and topoisomerase I inhibitor). Area: Oncology.

phase 3 Chemotherapy regimen (combination of antimetabolite and topoisomerase I inhibitor) Thymidylate synthase (5-FU), Topoisomerase I (irinotecan) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFIRI regimen (FOLFIRI regimen) — National Cancer Institute (NCI). FOLFIRI is a chemotherapy regimen that combines three drugs to inhibit DNA synthesis and cell division, primarily targeting rapidly dividing cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FOLFIRI regimen TARGET	FOLFIRI regimen	National Cancer Institute (NCI)	phase 3	Chemotherapy regimen (combination of antimetabolite and topoisomerase I inhibitor)	Thymidylate synthase (5-FU), Topoisomerase I (irinotecan)
"FOLFIRI" cures	"FOLFIRI" cures	Centre Hospitalier Universitaire Dijon	phase 3	Chemotherapy regimen (combination of antimetabolite and topoisomerase I inhibitor)	Thymidylate synthase (5-FU), Topoisomerase I (irinotecan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen (combination of antimetabolite and topoisomerase I inhibitor) class)

Centre Hospitalier Universitaire Dijon · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFIRI regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/folfiri-regimen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab